New Method to Slow Brain Aging
By William Faloon And Cynthia Richards
Until recently, Alzheimer’s disease was viewed as an incurable consequence of aging.
Nearly everyone predicted an explosion of dementia victims as the Baby Boomer population matures past 60 years.
That pessimistic theory was turned upside down in a landmark 2016 report. This study, published in the New England Journal of Medicine, reveals that overall dementia incidence declined by about 10%-20% per decade starting in the 1980s.1
We at Life Extension® attribute the decline in dementia to Americans adopting healthier dietary/lifestyle practices, along with more aggressive interventions to protect vascular health. Solid research findings substantiate our position.2-20
Steps people can take today to reduce dementia risk include protecting against inflammation,21-26 hypertension,27-29 and mitochondrial dysfunction.26,30-35
Missing from this prevention strategy up until now is a way to reverse the structural changes observed in brain cells of Alzheimer’s patients.
This article reveals a novel and low-cost method of restoring cognitive function lost to normal aging.
In order to understand how Alzheimer’s dementia develops, you should know the structural damage that occurs in your brain as a part of normal aging.
The major structural defects are:
- Beta amyloid accumulation: Amyloid plaques are senile protein “clumps” that damage areas involved in memory consolidation. These plaques are highly toxic to neurons (brain cells).
- Tau protein dysfunction: Healthy neurons are held together by a cellular skeleton made up of tau protein microtubules. When tau proteins are dysfunctional36 and abnormally accumulate,37 the consequence is cellular death.
- Neurofibrillary tangles: As damaged tau proteins accumulate, neurons become clogged with neurofibrillary tangles.38 This renders neurons dysfunctional.
In a stunning development, two natural factors have been discovered that protect against structural brain cell alterations observed in the elderly. These new neuro-protectors are microdose lithium and a colostrum-derived proline-rich polypeptide.
Published studies reveal how these two nutrients can stabilize cognitive function, slow Alzheimer’s progression and possibly reverse it. These discoveries provide an easy way to protect against senile changes that up until now were thought to be unavoidable.
Lithium acts by inhibiting an enzyme called GSK-3 that causes the formation of abnormaltau proteins39 and neurofibrillary tangles. These “tangles” destroy brain cells and impair memory.40,41
Proline-rich polypeptide alters the expression of genes involved in beta amyloid formation and in tau protein damage that contributes to brain cell destruction.42,43
This “mother’s milk” extract has been shown to produce meaningful improvements in cognitive function and daily living activities in human studies. Additional research demonstrates an increase in new nerve cell growth and connectivity.43,44
This article will focus on an unprecedented opportunity for aging humans to halt certain mechanisms of brain aging using very low-cost nutrients.
What should excite Life Extension supporters is that the mechanisms by which these nutrients protect the brain may confer similar benefits to cells in other parts of the aging body.
These discoveries open new fields of innovation to target the underlying causes of degenerative aging.
GSK-3: The Age-Accelerating Enzyme
Researchers have made a discovery so profound that it might surpass other known mechanisms of pathological aging in importance.
Our bodies contain an enzyme called GSK-3 that plays a role in regulating glucose metabolism. GSK-3 stands for glycogen synthase kinase-3. The problem with GSK-3 as we age is that it severely damages our delicate cellular structures.
Here’s a description of what scientists find when GSK-3 activity is increased:
- Accelerated aging in heart and muscle, showing profound dysfunction.45
- Increase in pro-inflammatory cytokines.45
- Accelerated aging in the skeletal system, leading to degenerative joint disease.45
- Accelerated aging in the stomach and liver.45
- Development of structurally abnormal cell organelles including disrupted mitochondria.45
- Dysfunctional autophagy, meaning inability to clear “debris” that accumulates inside aging cells.45
- Development of type II diabetes,46 Alzheimer’s and other disorders.47
You are about to learn a new term that may soon become as widely known as “antioxidant.”
This new longevity strategy is to identify safe substances that function as GSK-3 inhibitors. Studies show that when GSK-3 is inhibited, healthy lifespan may be increased.48
How GSK-3 Contributes to Alzheimer’s disease
Alzheimer’s disease brains undergo structural changes that result in accumulations of beta amyloid plaque and damaged tau proteins.49 This in turn createsneurofibrillary tangles that lead to brain shrinkage and cell death associated with Alzheimer’s dementia.50
These structural alterations in brain cells correlate with increased activity of the GSK-3 enzyme.
GSK-3 converts tau proteins into destructive tangled clumps that poison brain cells. The abnormal expression of tau proteins caused by GSK-3 can lead to neurofibrillary tangle formation and eventual dementia.39,50,51
Evidence suggests that impaired glucose/insulin action increases accumulations of beta amyloid and damaged tau proteins.50
These observations have led to the term “type III diabetes” being used to describe Alzheimer’s disease. That’s because so many Alzheimer’s patients also present with glucose impairment and insulin resistance.52,53
Studies have shown that by inhibiting GSK-3 activity, one can effectively lower blood glucose in diabetic animals, while increasing insulin sensitivity.54,55
Since Alzheimer’s patients frequently suffer from abnormal sugar and insulin action in their brains, this has led to the idea that GSK-3 inhibition might be a useful approach in Alzheimer’s disease.51 In fact, the title of a comprehensive scientific report on this topic is:
“GSK-3 is essential in the pathogenesis of Alzheimer’s disease”39
Lithium: A GSK-3 Inhibitor
You don’t have to wait for pharmaceutical research to resolve the devastating impact inflicted by excess GSK-3. That’s because a GSK-3 inhibitor already exists and holds tremendous promise in the fight against Alzheimer’s. This GSK-3 inhibitor is the trace element lithium.
Lithium has a long history in medicine as a psychoactive drug.56 It has also been shown to be an important component for cognitive and mental health.57-59
Epidemiologic studies show a strong association between low lithium levels in drinking water and high rates of suicide and homicide, suggesting that insufficient lithium contributes to mental destabilization.60 Because lithium intake from natural sources varies widely, this has led to speculation that many of us are failing to consume the element in quantities large enough to provide natural neuroprotection.5
And that, in turn, means that there may be real benefits in increasing our regular consumption of lithium by tiny amounts, on a regular basis. We now have persuasive evidence on how microdose lithium exerts robust brain-protective effects.
Lithium Reduces Brain Plaque Accumulation
The GSK-3 enzyme causes neurofibrillary tangles to aggregate, which is a structural defect observed in Alzheimer’s disease.40
At much lower doses than used in psychiatric treatment, lithium inhibits GSK-3.41
Just as humans do, fruit flies accumulate beta amyloid as they age and demonstrate progressive brain cell dysfunction. They therefore serve as a surrogate model to ascertain structural changes that occur in aged human brains. In fruit fly models of Alzheimer’s,lithium was shown to inhibit action of the GSK-3 enzyme, resulting in a reduction of beta amyloid toxicity to brain cells.40,41
In a separate study of fruit flies, lithium administered either throughout adulthood or only later in life extended lifespan, in part by means of GSK-3 inhibition.48 This study showed the profound impacts of GSK-3, an effect that is now being seen in higher vertebrates as well.
In a mouse model of Alzheimer’s disease, researchers studied the effects of microdose lithium, in amounts 1,000-fold smaller than those used in human psychiatry.61 These mice were supplied with lithium carbonate in drinking water, beginning in early and middle adulthood, while treating control animals with water alone.
By the end of treatment, there was no memory disruption seen in any of the Alzheimer’s or normal mice who were ingesting thelithium water. The Alzheimer’s-prone mice that drank water without lithium had significant disruption of memory during tasks.
In other words, the Alzheimer’s-model mice that were treated with lithium in their drinking water retained the memory and cognitive performance of normal mice.
Mice treated with lithium from early adulthood onward also showed a decrease in beta amyloid plaques in their brains, had no loss of neurons in memory centers of the brain, and had higher levels of protective brain-derived neurotrophic factor compared with non-treated animals.61 This would be an astonishing finding if replicated in humans.
Indeed, there is now growing evidence for just such an effect on human memory and behavioral characteristics.
Human Study Shows that Lithium Preserves Cognition
Lithium at microdoses in humans shows cognition-preserving effects.
A study involving Alzheimer’s patients was conducted using microdose lithium, administered at 300 mcg per day for 15 months.59 Cognitive impairment was evaluated by scores on the Mini-Mental State Examination.63
At the outset of the study there were no significant differences in Mini-Mental State Examination scores between treated and control Alzheimer’s subjects. The maximum Mini-Mental State Examination score is 30 points. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.
By 90 days, statistical analysis revealed that Alzheimer’s subjects treated with microdose lithium had cognitive performance scores that remained stable, while patients taking the placebo experienced a decrease in cognitive performance scores. The placebo group of Alzheimer’s patients was approximately 3 points below the lithium-treated group (17.37 vs. 20.60) during the initial study period, and by the end of the study, placebo controls were approximately 5 points below the lithium-treated Alzheimer’s group (14 vs. 19.82).59
Astonishingly, this study demonstrated that there was virtually no further cognitive decline during the study period in Alzheimer’s patients supplemented with microdose lithium.
Proline-Rich Polypeptide Reverses Neurologic Decline
Derived from mother’s milk, colostrum,43 a proline-rich polypeptide, has been shown to influence gene expression in the immune system and brain.
Colostrum-derived proline-rich polypeptide is being studied for its ability to beneficially affect beta amyloid and damaged tau proteins.43
The ability of proline-rich polypeptide to favorably modulate neuronal structure is being translated into positive clinical findings when studied in Alzheimer’s patients.
Proline-Rich Polypeptide Lowers Beta Amyloid and Abnormal Tau Levels
In a lab study, proline-rich polypeptide altered the expression of genes involved in beta amyloid protein production and in the changes to tau proteins that trigger formation of neurofibrillary tangles.
At the same time, proline-rich polypeptide altered the expression of genes to increase the production ofenzymes that break down and eliminate beta amyloid as part of the natural clearance process.42
This study demonstrated additional protective effects of proline-rich polypeptide, including enhanced defenses against chemical stresses and decreased expression of cytokines that promote inflammation, a process long implicated in Alzheimer’s disease.42
Together, these properties of proline-rich polypeptide change the expression of molecular networks that lead to beta amyloid formation and tau alterations. This mother’s milk-derived compound thus has the potential to prevent some of the fundamental structural causes of Alzheimer’s disease!
Proline-Rich Polypeptide Improves Cognitive Performance
Compelling laboratory studies demonstrate that proline-rich polypeptide, when applied to nerve cells growing in culture, triggers a cascade of events very similar to that produced by natural nerve growth factor.
These structural effects include important brain benefits such as enhanced differentiation of premature cells into functioning adult neurons, and increased outgrowth of neurites, the tiny projections on nerve cells where cell-to-cell communication takes place.43,44
A study was done on senescence-accelerated mice, which age at a much higher rate than do normal mice. They were fed either colostrum-derived proline-rich polypeptide, colostrum, or a mixture of cow-derived proteins.71 The mice were then subjected to a battery of behavioral tests to study spatial learning and memory.
In the group fed colostrum-derived proline-rich polypeptide, but not the others, learning and memory capabilities were found to be significantly improved as the animals aged, and the median lifespan was extended by 26%.
Reversal of Cognitive Decline in Human Alzheimer’s Patients
Studies of anti-Alzheimer’s drugs are considered successful when they show a slowing or stabilization of cognitive decline.
Human studies of colostrum-derived proline-rich polypeptide are showing not only stabilization, but also reversal of brain dysfunction in those with early-stage disease.
In one study, 46 patients with Alzheimer’s were randomly assigned to receive, every second day, either 100 mcg of colostrum-derived proline-rich polypeptide, 100 mcg of selenium, or placebo tablets.72 Subjects took the supplements for three weeks, followed by 2 weeks of no treatment, and repeated this cycle 10 times over the one-year trial. This dosing regimen was designed to maximize the impact of colostrum-derived proline-rich polypeptide, which can lose effectiveness when taken continuously without a regular time-out interval.72
Subjects were then assessed by psychiatrists blinded to the treatment assignment of each patient, using the standard Mini-Mental State Examination score.
In the proline-rich polypeptide group, 54% of Alzheimer’s patients showed improved scores (average improvement 25%). In the other 46% of Alzheimer’s patients receiving proline-rich polypeptide, the dementia progression stabilized (did not worsen). Patients with milder Alzheimer’s at the beginning of the study showed greater improvement than those who had more advanced disease, demonstrating the value of early intervention.
In the selenium-treated group, 7% of the patients saw improvement and 87% stabilized.
In the unfortunate placebo group, Alzheimer’s patients with mild and moderate disease saw their mental test scores decrease by36% and 55%, respectively. Scores of placebo patients with the most severe Alzheimer’s decreased by 31%.72
A second study by the same group of researchers, and using the same dose and dosing schedule, was performed to evaluate longer-term effects of treatment.73 In this study, however, no placebo group or selenium group was included.
Treatment continued for 16 months, but included a group (1/3 of the whole) who had participated in the earlier study, and so were in fact treated for a total of 28 months.
By the end of the study, significant improvements in Mini-Mental State Examination scores were seen at each interval, compared with baseline values.
The mental test score improvements of the Alzheimer’s patients who received proline-rich polypeptide are substantial and translate into an exciting new direction for future clinical studies.
A very low dose of the element lithium, along with natural colostrum-derived proline-rich polypeptide, has been shown in both animal and human studies to halt Alzheimer’s progression.
In the case of proline-rich polypeptide, 54% of Alzheimer’s patients were able to reverse the cognitive decline produced by the disease.
Lithium acts by inhibiting the destructive GSK-3 enzyme. GSK-3 is implicated in the chemical changes that cause abnormal tau proteins to form toxic neurofibrillary tangles, which destroy brain cells and impair memory.
Proline-rich polypeptide inhibits expression of genes involved in the production of beta amyloid and the abnormal expression of tau proteins, both of which contribute to neuronal destruction.
While no truly effective medication for Alzheimer’s exists,74,75 lithium and proline-rich polypeptide contribute to potential prevention of the structural changes that contribute to Alzheimer’s. They are safe enough for regular use over the long term, and should be included in a supplement regimen aimed at decelerating destructive aging processes.
As described at the beginning of this article, GSK-3 inhibitors not only confer protection against neuronal structural changes, but may protect other cells in the body against age-associated deterioration.
Based on the data uncovered in this article, if a pharmaceutical were developed that produced anywhere near these same clinical benefits, it would become a multibillion-dollar blockbuster drug that would cost consumers hundreds if not thousands of dollars per bottle.
The cost of these two nutrients, on the other hand, is remarkably low.
Alzheimer’s disease remains a looming threat for the aging population. Its consequences are devastating, not only for patients, but also for their families and caregivers.
The availability of a pharmaceutical that protects against damaging structural alterations of brain cells would represent a game-changing advance in medicine.
If this same pharmaceutical was able to halt and partially reverse age-associated cognitive decline in older individuals, it would likely become the most ubiquitously-prescribed drug in medical history.
The incredible news for consumers is that these kinds of cellular protective benefits can be found in the novel use of nutrients that cost less than 50 cents a day.
The findings about microdose lithium alone represent a new weapon against a destructive aging mechanism caused by excess GSK-3 activity.
As humans adopt widespread use of GSK-3 inhibitors, look for potential increases in functional human longevity.
If you have any questions on the scientific content of this article, please call a Life Extension® Wellness Specialist at 1-866-864-3027.
- Satizabal CL, Beiser AS, Chouraki V, et al. Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med. 2016;374(6):523-32.
- Conner TS, Brookie KL, Richardson AC, et al. On carrots and curiosity: eating fruit and vegetables is associated with greater flourishing in daily life. Br J Health Psychol. 2015;20(2):413-27.
- Morris MC, Tangney CC, Wang Y, et al. MIND diet associated with reduced incidence of Alzheimer’s disease. Alzheimers Dement. 2015;11(9):1007-14.
- Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-63.
- Shukitt-Hale B, Bielinski DF, Lau FC, et al. The beneficial effects of berries on cognition, motor behaviour and neuronal function in ageing. Br J Nutr. 2015;114(10):1542-9.
- Casadesus G, Shukitt-Hale B, Stellwagen HM, et al. Modulation of hippocampal plasticity and cognitive behavior by short-term blueberry supplementation in aged rats. Nutr Neurosci. 2004;7(5-6):309-16.
- Duffy KB, Spangler EL, Devan BD, et al. A blueberry-enriched diet provides cellular protection against oxidative stress and reduces a kainate-induced learning impairment in rats. Neurobiol Aging. 2008;29(11):1680-9.
- Galli RL, Bielinski DF, Szprengiel A, et al. Blueberry supplemented diet reverses age-related decline in hippocampal HSP70 neuroprotection. Neurobiol Aging. 2006;27(2):344-50.
- Joseph JA, Carey A, Brewer GJ, et al. Dopamine and Abeta-induced stress signaling and decrements in Ca2+ buffering in primary neonatal hippocampal cells are antagonized by blueberry extract. J Alzheimers Dis. 2007;11(4):433-46.
- Joseph JA, Denisova NA, Arendash G, et al. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr Neurosci. 2003;6(3):153-62.
- Joseph JA, Shukitt-Hale B, Denisova NA, et al. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. J Neurosci. 1999;19(18):8114-21.
- Kang JH, Ascherio A, Grodstein F. Fruit and vegetable consumption and cognitive decline in aging women. Ann Neurol. 2005;57(5):713-20.
- Oboh G, Akinyemi AJ, Ademiluyi AO, et al. Inhibitory effect of some tropical green leafy vegetables on key enzymes linked to Alzheimer’s disease and some pro-oxidant induced lipid peroxidation in rats’ brain. J Food Sci Technol. 2014;51(5):884-91.
- Shukitt-Hale B. Blueberries and neuronal aging. Gerontology. 2012;58(6):518-23.
- Shukitt-Hale B, Carey AN, Jenkins D, et al. Beneficial effects of fruit extracts on neuronal function and behavior in a rodent model of accelerated aging. Neurobiol Aging. 2007;28(8):1187-94.
- Zafra-Stone S, Yasmin T, Bagchi M, et al. Berry anthocyanins as novel antioxidants in human health and disease prevention. Mol Nutr Food Res. 2007;51(6):675-83.
- Baezner H, Blahak C, Poggesi A, et al. Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology. 2008;70(12):935-42.
- Verdelho A, Madureira S, Ferro JM, et al. Physical activity prevents progression for cognitive impairment and vascular dementia: results from the LADIS (Leukoaraiosis and Disability) study. Stroke. 2012;43(12):3331-5.
- Boxer AL, Kramer JH, Johnston K, et al. Executive dysfunction in hyperhomocystinemia responds to homocysteine-lowering treatment. Neurology. 2005;64(8):1431-4.
- Fujita S, Kawaguchi T, Uehara T, et al. Progress of leukoaraiosis is inhibited by correction of platelet hyper-aggregability. Int Psychogeriatr. 2005;17(4):689-98.
- Koyama A, O’Brien J, Weuve J, et al. The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2013;68(4):433-40.
- Ravaglia G, Forti P, Maioli F, et al. Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiol Aging. 2007;28(12):1810-20.
- Fuchs T, Trollor JN, Crawford J, et al. Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney Memory and Aging Study. Aging Cell.2013;12(5):882-9.
- Nguyen JC, Killcross AS, Jenkins TA. Obesity and cognitive decline: role of inflammation and vascular changes. Front Neurosci. 2014;8:375.
- Ferreira ST, Clarke JR, Bomfim TR, et al. Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer’s disease. Alzheimers Dement. 2014;10(1 Suppl):S76-83.
- De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes. 2014;63(7):2262-72.
- Yang D, Cabral D, Gaspard EN, et al. Cerebral Hemodynamics in the Elderly: A Transcranial Doppler Study in the Einstein Aging Study Cohort. J Ultrasound Med. 2016.
- Tzourio C. Hypertension, cognitive decline, and dementia: an epidemiological perspective. Dialogues Clin Neurosci. 2007;9(1):61-70.
- Paglieri C, Bisbocci D, Caserta M, et al. Hypertension and cognitive function. Clin Exp Hypertens. 2008;30(8):701-10.
- Mancuso M, Orsucci D, Siciliano G, et al. Mitochondria, mitochondrial DNA and Alzheimer’s disease. What comes first? Curr Alzheimer Res. 2008;5(5):457-68.
- Swerdlow RH, Burns JM, Khan SM. The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers Dis. 2010;20 Suppl 2:S265-79.
- Cui H, Kong Y, Zhang H. Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct. 2012;2012:646354.
- Cardoso S, Carvalho C, Correia SC, et al. Alzheimers disease: From mitochondrial perturbations to mitochondrial medicine. Brain Pathol. 2016.
- Scaglia F. The role of mitochondrial dysfunction in psychiatric disease. Dev Disabil Res Rev. 2010;16(2):136-43.
- Coskun PE, Wyrembak J, Derbereva O, et al. Systemic mitochondrial dysfunction and the etiology of Alzheimer’s disease and down syndrome dementia. J Alzheimers Dis. 2010;20 Suppl 2:S293-310.
- Cardenas AM, Ardiles AO, Barraza N, et al. Role of tau protein in neuronal damage in Alzheimer’s disease and Down syndrome. Arch Med Res. 2012;43(8):645-54.
- Mietelska-Porowska A, Wasik U, Goras M, et al. Tau Protein Modifications and Interactions: Their Role in Function and Dysfunction. International Journal of Molecular Sciences. 2014;15(3):4671-713.
- Brion JP. Neurofibrillary tangles and Alzheimer’s disease. Eur Neurol. 1998;40(3):130-40.
- Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis. 2006;9(3 Suppl):309-17.
- Sofola O, Kerr F, Rogers I, et al. Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer’s disease. PLoS Genet. 2010;6(9):e1001087.
- Sofola-Adesakin O, Castillo-Quan JI, Rallis C, et al. Lithium suppresses Abeta pathology by inhibiting translation in an adult Drosophila model of Alzheimer’s disease. Front Aging Neurosci. 2014;6:190.
- Szaniszlo P, German P, Hajas G, et al. New insights into clinical trial for Colostrinin in Alzheimer’s disease. J Nutr Health Aging. 2009;13(3):235-41.
- Boldogh I, Kruzel ML. Colostrinin: an oxidative stress modulator for prevention and treatment of age-related disorders. J Alzheimers Dis. 2008;13(3):303-21.
- Janusz M, Zablocka A. Colostrinin: a proline-rich polypeptide complex of potential therapeutic interest. Cell Mol Biol (Noisy-le-grand). 2013;59(1):4-11.
- Zhou J, Force T. Focusing the spotlight on GSK-3 in aging. Aging (Albany NY). 2013;5(6):388-9.
- Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets. 2006;7(11):1435-41.
- Lei P, Ayton S, Bush AI, et al. GSK-3 in Neurodegenerative Diseases. Int J Alzheimers Dis. 2011;2011:189246.
- Castillo-Quan JI, Li L, Kinghorn KJ, et al. Lithium Promotes Longevity through GSK3/NRF2-Dependent Hormesis. Cell Rep. 2016;15(3):638-50.
- Serrano-Pozo A, Frosch MP, Masliah E, et al. Neuropathological Alterations in Alzheimer Disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189.
- Chen Z, Zhong C. Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol. 2013;108:21-43.
- Chen S, Liu AR, An FM, et al. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4. Age (Dordr). 2012;34(5):1211-24.
- de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008;2(6):1101-13.
- Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease--is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63-80.
- Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov. 2004;3(6):479-87.
- MacAulay K, Woodgett JR. Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes. Expert Opin Ther Targets. 2008;12(10):1265-74.
- Motoi Y, Shimada K, Ishiguro K, et al. Lithium and autophagy. ACS Chem Neurosci. 2014;5(6):434-42.
- Schrauzer GN. Lithium: occurrence, dietary intakes, nutritional essentiality. J Am Coll Nutr. 2002;21(1):14-21.
- Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev. 2001(2):Cd003013.
- Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer Res. 2013;10(1):104-7.
- Schrauzer GN, Shrestha KP. Lithium in drinking water and the incidences of crimes, suicides, and arrests related to drug addictions. Biol Trace Elem Res. 1990;25(2):105-13.
- Nunes MA, Schowe NM, Monteiro-Silva KC, et al. Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer’s Disease. PLoS One. 2015;10(11):e0142267.
- Available at: https://www.ucl.ac.uk/news/news-articles/0416/070416-fruit-flies-live-longer-on-lithium. Accessed July 28, 2016.
- Pangman VC, Sloan J, Guse L. An examination of psychometric properties of the mini-mental state examination and the standardized mini-mental state examination: implications for clinical practice. Appl Nurs Res. 2000;13(4):209-13.
- Ishii N, Terao T, Araki Y, et al. Low risk of male suicide and lithium in drinking water. J Clin Psychiatry. 2015;76(3):319-26.
- Giotakos O, Tsouvelas G, Nisianakis P, et al. A negative association between lithium in drinking water and the incidences of homicides, in Greece. Biol Trace Elem Res. 2015;164(2):165-8.
- Helbich M, Leitner M, Kapusta ND. Lithium in drinking water and suicide mortality: interplay with lithium prescriptions. Br J Psychiatry. 2015;207(1):64-71.
- Kapusta ND, Mossaheb N, Etzersdorfer E, et al. Lithium in drinking water and suicide mortality. Br J Psychiatry. 2011;198(5):346-50.
- Mauer S, Vergne D, Ghaemi SN. Standard and trace-dose lithium: a systematic review of dementia prevention and other behavioral benefits. Aust N Z J Psychiatry. 2014;48(9):809-18.
- Available at: http://www.nytimes.com/2014/09/14/opinion/sunday/should-we-all-take-a-bit-of-lithium.html. Accessed July 28, 2016.
- Forlenza OV, de Paula VJ, Machado-Vieira R, et al. Does lithium prevent Alzheimer’s disease? Drugs Aging. 2012;29(5):335-42.
- Boldogh I, Aguilera L, German P, et al. Colostrinin Increases the Life-Span and Neurological Performance in Senescence Accelerated Mice. Neurodegenerative Dis. 2007;4(Suppl 1):264.
- Leszek J, Inglot AD, Janusz M, et al. Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer’s disease. A double-blind, placebo-controlled study. Arch Immunol Ther Exp (Warsz). 1999;47(6):377-85.
- Leszek J, Inglot AD, Janusz M, et al. Colostrinin proline-rich polypeptide complex from ovine colostrum—a long-term study of its efficacy in Alzheimer’s disease. Med Sci Monit. 2002;8(10):Pi93-6.
- Casey DA, Antimisiaris D, O’Brien J. Drugs for Alzheimer’s disease: are they effective? P t. 2010;35(4):208-11.
- Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord. 2013;6(1):19-33.